Active ingredient: Iron (Iron Acetyltransferrin)

advertisement
How is the drug helping you?

Iron (Iron Acetyltransferrin) uses


1 INDICATIONS AND USAGE

Iron (Iron Acetyltransferrin) is indicated for the treatment of Iron (Iron Acetyltransferrin) deficiency anemia in patients with chronic kidney disease (CKD).

Iron (Iron Acetyltransferrin) is an Iron (Iron Acetyltransferrin) replacement product indicated for the treatment of Iron (Iron Acetyltransferrin) deficiency anemia in patients with chronic kidney disease (CKD). (1)

2 DOSAGE AND ADMINISTRATION

Iron must only be administered intravenously either by slow injection or by infusion. The dosage of Iron (Iron Acetyltransferrin) is expressed in mg of elemental Iron (Iron Acetyltransferrin). Each mL contains 20 mg of elemental Iron (Iron Acetyltransferrin).

Population Dose
Adult patients Hemodialysis Dependent-Chronic Kidney Disease (HDD-CKD) (2.1) 100 mg slow intravenous injection or infusion
Non-Dialysis Dependent-Chronic Kidney Disease (NDD-CKD) (2.2) 200 mg slow intravenous injection or infusion
Peritoneal Dialysis Dependent-Chronic Kidney Disease (PDD-CKD) (2.3) 300 mg or 400 mg intravenous infusion
Pediatric patients HDD-CKD (2.4), PDD-CKD or NDD-CKD (2.5) 0.5 mg/kg slow intravenous injection or infusion

2.1 Adult Patients with Hemodialysis Dependent-Chronic Kidney Disease (HDD-CKD)

Administer Iron (Iron Acetyltransferrin) 100 mg undiluted as a slow intravenous injection over 2 to 5 minutes, or as an infusion of 100 mg diluted in a maximum of 100 mL of 0.9% NaCl over a period of at least 15 minutes, per consecutive hemodialysis session. Iron (Iron Acetyltransferrin) should be administered early during the dialysis session. The usual total treatment course of Iron (Iron Acetyltransferrin) is 1000 mg. Iron (Iron Acetyltransferrin) treatment may be repeated if Iron (Iron Acetyltransferrin) deficiency reoccurs.

2.2 Adult Patients with Non-Dialysis Dependent-Chronic Kidney Disease

Administer Iron (Iron Acetyltransferrin) 200 mg undiluted as a slow intravenous injection over 2 to 5 minutes or as an infusion of 200 mg in a maximum of 100 mL of 0.9% NaCl over a period of 15 minutes. Administer on 5 different occasions over a 14 day period. There is limited experience with administration of an infusion of 500 mg of Iron (Iron Acetyltransferrin), diluted in a maximum of 250 mL of 0.9% NaCl, over a period of 3.5 to 4 hours on Day 1 and Day 14. Iron (Iron Acetyltransferrin) treatment may be repeated if Iron (Iron Acetyltransferrin) deficiency reoccurs.

2.3 Adult Patients with Peritoneal Dialysis Dependent-Chronic Kidney Disease

Administer Iron (Iron Acetyltransferrin) in 3 divided doses, given by slow intravenous infusion, within a 28 day period: 2 infusions each of 300 mg over 1.5 hours 14 days apart followed by one 400 mg infusion over 2.5 hours 14 days later. Dilute Iron (Iron Acetyltransferrin) in a maximum of 250 mL of 0.9% NaCl. Iron (Iron Acetyltransferrin) treatment may be repeated if Iron (Iron Acetyltransferrin) deficiency reoccurs.

2.4 Pediatric Patients with HDD-CKD for Iron (Iron Acetyltransferrin) maintenance treatment

The dosing for Iron (Iron Acetyltransferrin) replacement treatment in pediatric patients with HDD-CKD has not been established.

For Iron (Iron Acetyltransferrin) maintenance treatment: Administer Iron (Iron Acetyltransferrin) at a dose of 0.5 mg/kg, not to exceed 100 mg per dose, every two weeks for 12 weeks given undiluted by slow intravenous injection over 5 minutes or diluted in 25 mL of 0.9% NaCl and administered over 5 to 60 minutes. Iron (Iron Acetyltransferrin) treatment may be repeated if necessary.

2.5 Pediatric Patients with NDD-CKD or PDD-CKD who are on erythropoietin therapy for Iron (Iron Acetyltransferrin) maintenance treatment

The dosing for Iron (Iron Acetyltransferrin) replacement treatment in pediatric patients with NDD-CKD or PDD-CKD has not been established.

For Iron (Iron Acetyltransferrin) maintenance treatment: Administer Iron (Iron Acetyltransferrin) at a dose of 0.5 mg/kg, not to exceed 100 mg per dose, every four weeks for 12 weeks given undiluted by slow intravenous injection over 5 minutes or diluted in 25 mL of 0.9% NaCl and administered over 5 to 60 minutes. Iron (Iron Acetyltransferrin) treatment may be repeated if necessary.

advertisement

3 DOSAGE FORMS AND STRENGTHS

  • 10 mL single-use vial / 200 mg elemental Iron (Iron Acetyltransferrin) (20 mg/mL)
  • 5 mL single-use vial / 100 mg elemental Iron (Iron Acetyltransferrin) (20 mg/mL)
  • 2.5 mL single-use vial / 50 mg elemental Iron (Iron Acetyltransferrin) (20 mg/mL)
  • 10 mL single-use vial / 200 mg elemental Iron (Iron Acetyltransferrin) (20 mg/mL) (3)
  • 5 mL single-use vial / 100 mg elemental Iron (Iron Acetyltransferrin) (20 mg/mL) (3)
  • 2.5 mL single-use vial / 50 mg elemental Iron (Iron Acetyltransferrin) (20 mg/mL) (3)

4 CONTRAINDICATIONS

  • Known hypersensitivity to Iron (Iron Acetyltransferrin)
  • Known hypersensitivity to Iron (Iron Acetyltransferrin) (4)

5 WARNINGS AND PRECAUTIONS

  • Hypersensitivity Reactions: Observe for signs and symptoms of hypersensitivity during and after Iron administration for at least 30 minutes and until clinically stable following completion of each administration. Only administer Iron (Iron Acetyltransferrin) when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. (5.1)
  • Hypotension: Iron (Iron Acetyltransferrin) may cause hypotension. Monitor for signs and symptoms of hypotension during and following each administration of Iron (Iron Acetyltransferrin). (5.2)
  • Iron (Iron Acetyltransferrin) Overload: Regularly monitor hematologic responses during Iron (Iron Acetyltransferrin) therapy. Do not administer Iron (Iron Acetyltransferrin) to patients with Iron (Iron Acetyltransferrin) overload. (5.3)

5.1 Hypersensitivity Reactions

Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Iron (Iron Acetyltransferrin). Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. If hypersensitivity reactions or signs of intolerance occur during administration, stop Iron (Iron Acetyltransferrin) immediately. Monitor patients for signs and symptoms of hypersensitivity during and after Iron (Iron Acetyltransferrin) administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Iron (Iron Acetyltransferrin) when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. Most reactions associated with intravenous Iron (Iron Acetyltransferrin) preparations occur within 30 minutes of the completion of the infusion .

5.2 Hypotension

Iron may cause clinically significant hypotension. Monitor for signs and symptoms of hypotension following each administration of Iron (Iron Acetyltransferrin). Hypotension following administration of Iron (Iron Acetyltransferrin) may be related to the rate of administration and/or total dose administered .

5.3 Iron (Iron Acetyltransferrin) Overload

Excessive therapy with parenteral Iron (Iron Acetyltransferrin) can lead to excess storage of Iron (Iron Acetyltransferrin) with the possibility of iatrogenic hemosiderosis. All adult and pediatric patients receiving Iron (Iron Acetyltransferrin) require periodic monitoring of hematologic and Iron (Iron Acetyltransferrin) parameters (hemoglobin, hematocrit, serum ferritin and transferrin saturation). Do not administer Iron (Iron Acetyltransferrin) to patients with evidence of Iron (Iron Acetyltransferrin) overload. Transferrin saturation (TSAT) values increase rapidly after intravenous administration of Iron (Iron Acetyltransferrin) sucrose; do not perform serum Iron (Iron Acetyltransferrin) measurements for at least 48 hours after intravenous dosing .

advertisement

6 ADVERSE REACTIONS

The following serious adverse reactions associated with Iron are described in other sections .

  • The most common adverse reactions (≥2%) following the administration of Iron (Iron Acetyltransferrin) are diarrhea, nausea, vomiting, headache, dizziness, hypotension, pruritus, pain in extremity, arthralgia, back pain, muscle cramp, injection site reactions, chest pain, and peripheral edema. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact American Regent, Inc. at 1-800-734-9236 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

6.1 Adverse Reactions in Clinical Trials

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug may not reflect the rates observed in practice.

Adverse Reactions in Adults Patients with CKD

Adverse Reactions in Adult Patients with CKD

The frequency of adverse reactions associated with the use of Iron has been documented in six clinical trials involving 231 patients with HDD-CKD, 139 patients with NDD-CKD and 75 patients with PDD-CKD. Treatment-emergent adverse reactions reported by ≥ 2% of treated patients in the six clinical trials for which the rate for Iron (Iron Acetyltransferrin) exceeds the rate for comparator are listed by indication in Table 1. Patients with HDD-CKD received 100 mg doses at 10 consecutive dialysis sessions until a cumulative dose of 1000 mg was administered. Patients with NDD-CKD received either 5 doses of 200 mg over 2 weeks or 2 doses of 500 mg separated by fourteen days, and patients with PDD-CKD received 2 doses of 300 mg followed by a dose of 400 mg over a period of 4 weeks.


* EPO=Erythropoietin

Adverse Reactions

(Preferred Term)

HDD-CKD NDD-CKD PDD-CKD
Iron (Iron Acetyltransferrin) Iron (Iron Acetyltransferrin) Oral Iron (Iron Acetyltransferrin) Iron (Iron Acetyltransferrin) EPO* Only
(N=231) (N=139) (N=139) (N=75) (N=46)
% % % % %
Subjects with any adverse reaction 78.8 76.3 73.4 72.0 65.2
Ear and Labyrinth Disorders
Ear Pain 0 2.2 0.7 0 0
Eye Disorders
Conjunctivitis 0.4 0 0 2.7 0
Gastrointestinal Disorders
Abdominal pain 3.5 1.4 2.9 4.0 6.5
Diarrhea 5.2 7.2 10.1 8.0 4.3
Dysgeusia 0.9 7.9 0 0 0
Nausea 14.7 8.6 12.2 5.3 4.3
Vomiting 9.1 5.0 8.6 8.0 2.2
General Disorders and
Administration Site Conditions
Asthenia 2.2 0.7 2.2 2.7 0
Chest pain 6.1 1.4 0 2.7 0
Feeling abnormal 3.0 0 0 0 0
Infusion site pain or burning 0 5.8 0 0 0
Injection site extravasation 0 2.2 0 0 0
Peripheral edema 2.6 7.2 5.0 5.3 10.9
Pyrexia 3.0 0.7 0.7 1.3 0
Infections and Infestations
Nasopharyngitis, Sinusitis, Upper

respiratory tract infections, Pharyngitis

2.6 2.2 4.3 16.0 4.3
Injury, Poisoning and Procedural
Complications
Graft complication 9.5 1.4 0 0 0
Metabolism and Nutrition Disorders
Fluid overload 3.0 1.4 0.7 1.3 0
Gout 0 2.9 1.4 0 0
Hyperglycemia 0 2.9 0 0 2.2
Hypoglycemia 0.4 0.7 0.7 4.0 0
Musculoskeletal and Connective
Tissue Disorders
Arthralgia 3.5 1.4 2.2 4.0 4.3
Back pain 2.2 2.2 3.6 1.3 4.3
Muscle cramp 29.4 0.7 0.7 2.7 0
Myalgia 0 3.6 0 1.3 0
Pain in extremity 5.6 4.3 0 2.7 6.5
Nervous System Disorders
Dizziness 6.5 6.5 1.4 1.3 4.3
Headache 12.6 2.9 0.7 4.0 0
Respiratory, Thoracic and
Mediastinal Disorders
Cough 3.0 2.2 0.7 1.3 0
Dyspnea 3.5 5.8 1.4 1.3 2.2
Nasal congestion 0 1.4 2.2 1.3 0
Skin and Subcutaneous
Tissue Disorders
Pruritus 3.9 2.2 4.3 2.7 0
Vascular Disorders
Hypertension 6.5 6.5 4.3 8.0 6.5
Hypotension 39.4 2.2 0.7 2.7 2.2

One hundred thirty (11%) of the 1,151 patients evaluated in the 4 U.S. trials in HDD-CKD patients (studies A, B and the two post marketing studies) had prior other intravenous Iron (Iron Acetyltransferrin) therapy and were reported to be intolerant (defined as precluding further use of that Iron (Iron Acetyltransferrin) product). When these patients were treated with Iron (Iron Acetyltransferrin) there were no occurrences of adverse reactions that precluded further use of Iron (Iron Acetyltransferrin) .

Adverse Reactions in Pediatric Patients with CKD (ages 2 years and older)

Adverse Reactions in Pediatric Patients with CKD (ages 2 years and older)

In a randomized, open-label, dose-ranging trial for Iron (Iron Acetyltransferrin) maintenance treatment with Iron (Iron Acetyltransferrin) in pediatric patients with CKD on stable erythropoietin therapy , at least one treatment-emergent adverse reaction was experienced by 57% (27/47) of the patients receiving Iron (Iron Acetyltransferrin) 0.5 mg/kg, 53% (25/47) of the patients receiving Iron (Iron Acetyltransferrin) 1.0 mg/kg, and 55% (26/47) of the patients receiving Iron (Iron Acetyltransferrin) 2.0 mg/kg.

A total of 5 (11%) subjects in the Iron (Iron Acetyltransferrin) 0.5 mg/kg group, 10 (21%) patients in the Iron (Iron Acetyltransferrin) 1.0 mg/kg group, and 10 (21%) patients in the Iron (Iron Acetyltransferrin) 2.0 mg/kg group experienced at least 1 serious adverse reaction during the study. The most common treatment-emergent adverse reactions (> 2% of patients) in all patients were headache (6%), respiratory tract viral infection (4%), peritonitis (4%), vomiting (4%), pyrexia (4%), dizziness (4%), cough (4%), renal transplant (4%), nausea (3%), arteriovenous fistula thrombosis (2%), hypotension (2%), and hypertension (2.1%).

6.2 Adverse Reactions from Post-Marketing Experience

Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

In the post-marketing safety studies in 1,051 treated patients with HDD-CKD, the adverse reactions reported by > 1% were: cardiac failure congestive, sepsis and dysgeusia.

The following adverse reactions have been identified during post-approval use of Iron (Iron Acetyltransferrin). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: Anaphylactic-type reactions, shock, loss of consciousness, collapse, bronchospasm, dyspnea, convulsions, light-headedness, confusion, angioedema, swelling of the joints, hyperhidrosis, back pain, bradycardia, and chromaturia.

Symptoms associated with Iron (Iron Acetyltransferrin) total dosage or infusing too rapidly included hypotension, dyspnea, headache, vomiting, nausea, dizziness, joint aches, paresthesia, abdominal and muscle pain, edema, and cardiovascular collapse. These adverse reactions have occurred up to 30 minutes after the administration of Iron (Iron Acetyltransferrin) injection. Reactions have occurred following the first dose or subsequent doses of Iron (Iron Acetyltransferrin). Symptoms may respond to intravenous fluids, hydrocortisone, and/or antihistamines. Slowing the infusion rate may alleviate symptoms.

Injection site discoloration has been reported following extravasation. Assure stable intravenous access to avoid extravasation.

advertisement

7 DRUG INTERACTIONS

Drug interactions involving Iron (Iron Acetyltransferrin) have not been studied. However, Iron (Iron Acetyltransferrin) may reduce the absorption of concomitantly administered oral Iron (Iron Acetyltransferrin) preparations.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category B

Pregnancy Category B

There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, Iron sucrose was administered intravenously to rats and rabbits during the period of organogenesis at doses up to 13 mg/kg/day of elemental Iron (Iron Acetyltransferrin) (half or equivalent to the maximum recommended human dose based on body surface area, respectively) and revealed no evidence of harm to the fetus due to Iron (Iron Acetyltransferrin) sucrose. Because animal reproductive studies are not always predictive of human response, Iron (Iron Acetyltransferrin) should be used during pregnancy only if clearly needed.

8.3 Nursing Mothers

It is not known whether Iron (Iron Acetyltransferrin) sucrose is excreted in human milk. Iron (Iron Acetyltransferrin) sucrose is secreted into the milk of lactating rats. Because many drugs are excreted in human milk, caution should be exercised when Iron (Iron Acetyltransferrin) is administered to a nursing woman.

8.4 Pediatric Use

Safety and effectiveness of Iron for Iron (Iron Acetyltransferrin) replacement treatment in pediatric patients with dialysis-dependent or non-dialysis-dependent CKD have not been established.

Safety and effectiveness of Iron (Iron Acetyltransferrin) for Iron (Iron Acetyltransferrin) maintenance treatment in pediatric patients 2 years of age and older with dialysis-dependent or non-dialysis-dependent CKD receiving erythropoietin therapy were studied. Iron (Iron Acetyltransferrin) at doses of 0.5 mg/kg, 1.0 mg/kg, and 2.0 mg/kg was administered. All three doses maintained hemoglobin between 10.5 g/dL and 14.0 g/dL in about 50% of subjects over the 12-week treatment period with stable EPO dosing. [See Clinical Studies (14.6)]

Iron (Iron Acetyltransferrin) has not been studied in patients younger than 2 years of age.

In a country where Iron (Iron Acetyltransferrin) is available for use in children, at a single site, five premature infants (weight less than 1,250 g) developed necrotizing enterocolitis and two of the five died during or following a period when they received Iron (Iron Acetyltransferrin), several other medications and erythropoietin. Necrotizing enterocolitis may be a complication of prematurity in very low birth weight infants. No causal relationship to Iron (Iron Acetyltransferrin) or any other drugs could be established.

8.5 Geriatric Use

Clinical studies of Iron (Iron Acetyltransferrin) did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently from younger subjects. Of the 1,051 patients in two post-marketing safety studies of Iron (Iron Acetyltransferrin), 40% were 65 years and older. No overall differences in safety were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. In general, dose administration to an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

advertisement

10 OVERDOSAGE

No data are available regarding overdosage of Iron (Iron Acetyltransferrin) in humans. Excessive dosages of Iron (Iron Acetyltransferrin) may lead to accumulation of Iron (Iron Acetyltransferrin) in storage sites potentially leading to hemosiderosis. Do not administer Iron (Iron Acetyltransferrin) to patients with Iron (Iron Acetyltransferrin) overload.

Toxicities in single-dose studies in mice and rats, at intravenous Iron (Iron Acetyltransferrin) sucrose doses up to 8 times the maximum recommended human dose based on body surface area, included sedation, hypoactivity, pale eyes, bleeding in the gastrointestinal tract and lungs, and mortality.

11 DESCRIPTION

Iron (Iron Acetyltransferrin) (iron sucrose injection, USP), an Iron (Iron Acetyltransferrin) replacement product, is a brown, sterile, aqueous, complex of polynuclear Iron (Iron Acetyltransferrin) (III)-hydroxide in sucrose for intravenous use. Iron (Iron Acetyltransferrin) sucrose injection has a molecular weight of approximately 34,000 to 60,000 daltons and a proposed structural formula:

[Na2Fe5O8(OH) ·3(H2O)]n ·m(C12H22O11)

where: n is the degree of Iron (Iron Acetyltransferrin) polymerization and m is the number of sucrose molecules associated with the Iron (Iron Acetyltransferrin) (III)-hydroxide.

Each mL contains 20 mg elemental Iron (Iron Acetyltransferrin) as Iron (Iron Acetyltransferrin) sucrose in water for injection. Iron (Iron Acetyltransferrin) is available in 10 mL single-use vials (200 mg elemental Iron (Iron Acetyltransferrin) per 10 mL), 5 mL single-use vials (100 mg elemental Iron (Iron Acetyltransferrin) per 5 mL), and 2.5 mL single-use vials (50 mg elemental Iron (Iron Acetyltransferrin) per 2.5 mL). The drug product contains approximately 30% sucrose w/v (300 mg/mL) and has a pH of 10.5 to 11.1. The product contains no preservatives. The osmolarity of the injection is 1,250 mOsmol/L.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Iron is an aqueous complex of poly-nuclear Iron (Iron Acetyltransferrin) (III)-hydroxide in sucrose. Following intravenous administration, Iron (Iron Acetyltransferrin) is dissociated into Iron (Iron Acetyltransferrin) and sucrose and the Iron (Iron Acetyltransferrin) is transported as a complex with transferrin to target cells including erythroid precursor cells. The Iron (Iron Acetyltransferrin) in the precursor cells is incorporated into hemoglobin as the cells mature into red blood cells.

12.2 Pharmacodynamics

Following intravenous administration, Iron (Iron Acetyltransferrin) is dissociated into Iron (Iron Acetyltransferrin) and sucrose. In 22 patients undergoing hemodialysis and receiving erythropoietin (recombinant human erythropoietin) therapy treated with Iron (Iron Acetyltransferrin) sucrose containing 100 mg of Iron (Iron Acetyltransferrin), three times weekly for three weeks, significant increases in serum Iron (Iron Acetyltransferrin) and serum ferritin and significant decreases in total Iron (Iron Acetyltransferrin) binding capacity occurred four weeks from the initiation of Iron (Iron Acetyltransferrin) sucrose treatment.

12.3 Pharmacokinetics

In healthy adults administered intravenous doses of Iron, its Iron (Iron Acetyltransferrin) component exhibited first order kinetics with an elimination half-life of 6 h, total clearance of 1.2 L/h, and steady state apparent volume of distribution of 7.9 L. The Iron (Iron Acetyltransferrin) component appeared to distribute mainly in blood and to some extent in extravascular fluid. A study evaluating Iron (Iron Acetyltransferrin) containing 100 mg of Iron (Iron Acetyltransferrin) labeled with 52Fe/59Fe in patients with Iron (Iron Acetyltransferrin) deficiency showed that a significant amount of the administered Iron (Iron Acetyltransferrin) is distributed to the liver, spleen and bone marrow and that the bone marrow is an irreversible Iron (Iron Acetyltransferrin) trapping compartment.

Following intravenous administration of Iron (Iron Acetyltransferrin), Iron (Iron Acetyltransferrin) sucrose is dissociated into Iron (Iron Acetyltransferrin) and sucrose. The sucrose component is eliminated mainly by urinary excretion. In a study evaluating a single intravenous dose of Iron (Iron Acetyltransferrin) containing 1,510 mg of sucrose and 100 mg of Iron (Iron Acetyltransferrin) in 12 healthy adults (9 female, 3 male: age range 32 to 52), 68.3% of the sucrose was eliminated in urine in 4 h and 75.4% in 24 h. Some Iron (Iron Acetyltransferrin) was also eliminated in the urine. Neither transferrin nor transferrin receptor levels changed immediately after the dose administration. In this study and another study evaluating a single intravenous dose of Iron (Iron Acetyltransferrin) sucrose containing 500 to 700 mg of Iron (Iron Acetyltransferrin) in 26 patients with anemia on erythropoietin therapy (23 female, 3 male; age range 16 to 60), approximately 5% of the Iron (Iron Acetyltransferrin) was eliminated in urine in 24 h at each dose level. The effects of age and gender on the pharmacokinetics of Iron (Iron Acetyltransferrin) have not been studied.

Pharmacokinetics in Pediatric Patients

Pharmacokinetics in Pediatric Patients

In a single-dose PK study of Iron (Iron Acetyltransferrin), patients with NDD-CDK ages 12 to 16 (N=11) received intravenous bolus doses of Iron (Iron Acetyltransferrin) at 7 mg/kg (maximum 200 mg) administered over 5 minutes. Following single dose Iron (Iron Acetyltransferrin), the half-life of total serum Iron (Iron Acetyltransferrin) was 8 hours. The mean Cmax and AUC values were 8545 μg/dl and 31305 hr-μg/dL, respectively, which were 1.42- and 1.67-fold higher than dose adjusted adult Cmax and AUC values.

Iron (Iron Acetyltransferrin) is not dialyzable through CA210 (Baxter) High Efficiency or Fresenius F80A High Flux dialysis membranes. In in vitro studies, the amount of Iron (Iron Acetyltransferrin) sucrose in the dialysate fluid was below the levels of detection of the assay (less than 2 parts per million).

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenicity studies have not been performed with Iron (Iron Acetyltransferrin) sucrose.

Iron (Iron Acetyltransferrin) sucrose was not mutagenic in vitro in the bacterial reverse mutation assay (Ames test) or the mouse lymphoma assay. Iron (Iron Acetyltransferrin) sucrose was not clastogenic in the in vitro chromosome aberration assay using human lymphocytes or in the in vivo mouse micronucleus assay.

Iron (Iron Acetyltransferrin) sucrose at intravenous doses up to 15 mg/kg/day of elemental Iron (Iron Acetyltransferrin) (1.2 times the maximum recommended human dose based on body surface area) had no effect on fertility and reproductive function of male and female rats.

14 CLINICAL STUDIES

Five clinical trials involving 647 adult patients and one clinical trial involving 131 pediatric patients were conducted to assess the safety and efficacy of Iron.

14.1 Study A: Hemodialysis Dependent-Chronic Kidney Disease (HDD–CKD)

Study A was a multicenter, open-label, historically-controlled study in 101 patients with HDD-CKD (77 patients with Iron (Iron Acetyltransferrin) treatment and 24 in the historical control group) with Iron (Iron Acetyltransferrin) deficiency anemia. Eligibility criteria for Iron (Iron Acetyltransferrin) treatment included patients undergoing chronic hemodialysis, receiving erythropoietin, hemoglobin level between 8.0 and 11.0 g/dL, transferrin saturation < 20%, and serum ferritin < 300 ng/mL. The mean age of the patients was 65 years with the age range of 31 to 85 years. Of the 77 patients, 44 (57%) were male and 33 (43%) were female.

Iron (Iron Acetyltransferrin) 100 mg was administered at 10 consecutive dialysis sessions either as slow injection or a slow infusion. The historical control population consisted of 24 patients with similar ferritin levels as patients treated with Iron (Iron Acetyltransferrin), who were off intravenous Iron (Iron Acetyltransferrin) for at least 2 weeks and who had received erythropoietin therapy with hematocrit averaging 31 to 36 for at least two months prior to study entry. The mean age of patients in the historical control group was 56 years, with an age range of 29 to 80 years. Patient age and serum ferritin level were similar between treatment and historical control patients.

Patients in the Iron (Iron Acetyltransferrin) treated population showed a greater increase in hemoglobin and hematocrit than did patients in the historical control population. See Table 2.


**p < 0.01 and *p < 0.05 compared to historical control from ANCOVA analysis with baseline hemoglobin, serum ferritin and erythropoietin dose as covariates.


Efficacy

parameters

End of treatment 2 week follow-up 5 week follow-up
Iron (Iron Acetyltransferrin) (n=69 Historical Control (n=18) Iron (Iron Acetyltransferrin)

(n=73)

Historical Control

(n=18)

Iron (Iron Acetyltransferrin)

(n=71)

Historical

Control

(n=15)

Hemoglobin (g/dL) 1.0 ± 0.12** 0.0 ± 0.21 1.3 ± 0.14** -0.6 ± 0.24 1.2 ± 0.17* -0.1 ± 0.23
Hematocrit (%) 3.1 ± 0.37** -0.3 ± 0.65 3.6 ± 0.44** -1.2 ± 0.76 3.3 ± 0.54 0.2 ± 0.86

Serum ferritin increased at endpoint of study from baseline in the Venofer-treated population (165.3 ± 24.2 ng/mL) compared to the historical control population (-27.6 ± 9.5 ng/mL). Transferrin saturation also increased at endpoint of study from baseline in the Venofer-treated population (8.8 ± 1.6%) compared to this historical control population (-5.1 ± 4.3%).

14.2 Study B: Hemodialysis Dependent-Chronic Kidney Disease

Study B was a multicenter, open label study of Iron (Iron Acetyltransferrin) in 23 patients with Iron (Iron Acetyltransferrin) deficiency and HDD-CKD who had been discontinued from Iron (Iron Acetyltransferrin) dextran due to intolerance. Eligibility criteria were otherwise identical to Study A. The mean age of the patients in this study was 53 years, with ages ranging from 21 to 79 years. Of the 23 patients enrolled in the study, 10 (44%) were male and 13 (56%) were female.

All 23 enrolled patients were evaluated for efficacy. Increases in mean hemoglobin (1.1 ± 0.2 g/dL), hematocrit (3.6 ± 0.6%), serum ferritin (266.3 ± 30.3 ng/mL) and transferrin saturation (8.7 ± 2.0%) were observed from baseline to end of treatment.

14.3 Study C: Hemodialysis Dependent-Chronic Kidney Disease

Study C was a multicenter, open-label study in patients with HDD-CKD. This study enrolled patients with a hemoglobin ≤ 10 g/dL, a serum transferrin saturation ≤ 20%, and a serum ferritin ≤ 200 ng/mL, who were undergoing maintenance hemodialysis 2 to 3 times weekly. The mean age of the patients enrolled in this study was 41 years, with ages ranging from 16 to 70 years. Of 130 patients evaluated for efficacy in this study, 68 (52%) were male and 62 (48%) were female. Forty-eight percent of the patients had previously been treated with oral Iron (Iron Acetyltransferrin). Exclusion criteria were similar to those in studies A and B. Iron (Iron Acetyltransferrin) was administered in doses of 100 mg during sequential dialysis sessions until a pre-determined (calculated) total dose of Iron (Iron Acetyltransferrin) was administered. A 50 mg dose (2.5 mL) was given to patients within two weeks of study entry as a test dose. Twenty-seven patients (20%) were receiving erythropoietin treatment at study entry and they continued to receive the same erythropoietin dose for the duration of the study.

The modified intention-to-treat (mITT) population consisted of 131 patients. Increases from baseline in mean hemoglobin (1.7 g/dL), hematocrit (5%), serum ferritin (434.6 ng/mL), and serum transferrin saturation (14%) were observed at week 2 of the observation period and these values remained increased at week 4 of the observation period.

14.4 Study D: Non-Dialysis Dependent-Chronic Kidney Disease

Study D was a randomized, open-label, multicenter, active-controlled study of the safety and efficacy of oral Iron (Iron Acetyltransferrin) versus Iron (Iron Acetyltransferrin) in patients with NDD-CKD with or without erythropoietin therapy. Erythropoietin therapy was stable for 8 weeks prior to randomization. In the study 188 patients with NDD-CKD, hemoglobin of ≤ 11.0 g/dL, transferrin saturation ≤ 25%, ferritin ≤ 300 ng/mL were randomized to receive oral Iron (Iron Acetyltransferrin) (325 mg ferrous sulfate three times daily for 56 days); or Iron (Iron Acetyltransferrin) (either 200 mg over 2 to 5 minutes 5 times within 14 days or two 500 mg infusions on Day 1 and Day 14, administered over 3.5 to 4 hours). The mean age of the 91 treated patients in the Iron (Iron Acetyltransferrin) group was 61.6 years (range 25 to 86 years) and 64 years (range 21 to 86 years) for the 91 patients in the oral Iron (Iron Acetyltransferrin) group.

A statistically significantly greater proportion of Iron (Iron Acetyltransferrin) subjects (35/79; 44.3%) compared to oral Iron (Iron Acetyltransferrin) subjects (23/82; 28%) had an increase in hemoglobin ≥ 1 g/dL at anytime during the study (p = 0.03).

14.5 Study E: Peritoneal Dialysis Dependent-Chronic Kidney Disease

Study E was a randomized, open-label, multicenter study comparing patients with PDD-CKD receiving an erythropoietin and intravenous Iron (Iron Acetyltransferrin) to patients with PDD-CKD receiving an erythropoietin alone without Iron (Iron Acetyltransferrin) supplementation. Patients with PDD-CKD, stable erythropoietin for 8 weeks, hemoglobin of ≤ 11.5 g/dL, TSAT ≤ 25%, ferritin ≤ 500 ng/mL were randomized to receive either no Iron (Iron Acetyltransferrin) or Iron (Iron Acetyltransferrin) (300 mg in 250 mL 0.9% NaCl over 1.5 hours on Day 1 and 15 and 400 mg in 250 mL 0.9% NaCl over 2.5 hours on Day 29). The mean age of the 75 treated patients in the Iron (Iron Acetyltransferrin) / erythropoietin group was 51.9 years (range 21 to 81 years) vs. 52.8 years (range 23 to 77 years) for 46 patients in the erythropoietin alone group.

Patients in the Iron (Iron Acetyltransferrin) / erythropoietin group had statistically significantly greater mean change from baseline to the highest hemoglobin value (1.3 g/dL), compared to subjects who received erythropoietin alone (0.6 g/dL) (p < 0.01). A greater proportion of subjects treated with Iron (Iron Acetyltransferrin) / erythropoietin (59.1 %) had an increase in hemoglobin of ≥ 1 g/dL at any time during the study compared to the subjects who received erythropoietin only (33.3%).

14.6 Study F: Iron Maintenance Treatment Dosing in Pediatric Patients Ages 2 years and Older with Chronic Kidney Disease

Study F was a randomized, open-label, dose-ranging study for Iron (Iron Acetyltransferrin) maintenance treatment in pediatric patients with dialysis-dependent or non-dialysis-dependent CKD on stable erythropoietin therapy. The study randomized patients to one of three doses of Iron (Iron Acetyltransferrin) (0.5 mg/kg, 1.0 mg/kg or 2.0 mg/kg). The mean age was 13 years (range 2 to 20 years). Over 70% of patients were 12 years or older in all three groups. There were 84 males and 61 females. About 60% of patients underwent hemodialysis and 25% underwent peritoneal dialysis in all three dose groups. At baseline, the mean hemoglobin was 12 g/dL, the mean TSAT was 33% and the mean ferritin was 300 ng/mL. Patients with HDD-CKD received Iron (Iron Acetyltransferrin) once every other week for 6 doses. Patients with PDD-CKD or NDD-CKD received Iron (Iron Acetyltransferrin) once every 4 weeks for 3 doses. Among 131 evaluable patients with stable erythropoietin dosing, the proportion of patients who maintained hemoglobin between 10.5 g/dL and 14.0 g/dL during the 12-week treatment period was 58.7%, 46.7%, and 45.0% in the Iron (Iron Acetyltransferrin) 0.5 mg/kg, 1.0 mg/kg, and 2.0 mg/kg groups, respectively. A dose-response relationship was not demonstrated.

16 HOW SUPPLIED/storage and handling

16.1 How Supplied

Iron is supplied sterile in 10 mL, 5 mL, and 2.5 mL single-use vials. Each 10 mL vial contains 200 mg elemental Iron (Iron Acetyltransferrin), each 5 mL vial contains 100 mg elemental Iron (Iron Acetyltransferrin), and each 2.5 mL vial contains 50 mg elemental Iron (Iron Acetyltransferrin) (20 mg/mL).

NDC-0517-2310-05 200 mg/10 mL Single-Use Vial Packages of 5
NDC-0517-2310-10 200 mg/10 mL Single-Use Vial Packages of 10
NDC-0517-2340-01 100 mg/5 mL Single-Use Vial Individually Boxed
NDC-0517-2340-10 100 mg/5 mL Single-Use Vial Packages of 10
NDC-0517-2340-25 100 mg/5 mL Single-Use Vial Packages of 25
NDC-0517-2340-99 100 mg/5 mL Single-Use Vial Packages of 10
NDC-0517-2325-10 50 mg/2.5 mL Single-Use Vial Packages of 10
NDC-0517-2325-25 50 mg/2.5 mL Single-Use Vial Packages of 25

16.2 Stability and Storage

Contains no preservatives. Store in original carton at 20°C to 25°C (68° F to 77° F); excursions permitted to 15° to 30°C (59° to 86°F).. Do not freeze.

Syringe Stability: Iron (Iron Acetyltransferrin), when diluted with 0.9% NaCl at concentrations ranging from 2 mg to 10 mg of elemental Iron (Iron Acetyltransferrin) per mL, or undiluted (20 mg elemental Iron (Iron Acetyltransferrin) per mL) and stored in a plastic syringe, was found to be physically and chemically stable for 7 days at controlled room temperature (25°C ± 2°C) and under refrigeration (4°C ± 2°C).

Intravenous Admixture Stability: Iron (Iron Acetyltransferrin), when added to intravenous infusion bags (PVC or non-PVC) containing 0.9% NaCl at concentrations ranging from 1 mg to 2 mg of elemental Iron (Iron Acetyltransferrin) per mL, has been found to be physically and chemically stable for 7 days at controlled room temperature (25°C ± 2°C).

Do not dilute to concentrations below 1 mg/mL.

Do not mix Iron (Iron Acetyltransferrin) with other medications or add to parenteral nutrition solutions for intravenous infusion.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to infusion.

17 PATIENT COUNSELING INFORMATION

Prior to Iron (Iron Acetyltransferrin) administration:

  • Question patients regarding any prior history of reactions to parenteral Iron (Iron Acetyltransferrin) products
  • Advise patients of the risks associated with Iron (Iron Acetyltransferrin)
  • Advise patients to report any symptoms of hypersensitivity that may develop during and following Iron (Iron Acetyltransferrin) administration, such as rash, itching, dizziness, light-headedness, swelling, and breathing problems [see Warnings and Precautions (5)]

AMERICAN

REGENT, INC.

SHIRLEY, NY 11967

Iron (Iron Acetyltransferrin) is manufactured under license from Vifor (International) Inc., Switzerland.

PremierProRx® is a trademark of Premier, Inc., used under license.

PREMIERProRx®

IN2340

MG #15727

Iron (Iron Acetyltransferrin) available forms, composition, doses:


Indications and Usages:

ATC codes:


ICD-10 codes:


Iron (Iron Acetyltransferrin) destination | category:


advertisement

Drugs with same active ingredients (Pharmaceutical companies):


References

  1. "Iron". https://pubchem.ncbi.nlm.nih.gov/co... (accessed August 28, 2018).
  2. "Iron". http://www.drugbank.ca/drugs/DB0159... (accessed August 28, 2018).
  3. "E1UOL152H7: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Dat... (accessed August 28, 2018).

Frequently asked Questions

Can i drive or operate heavy machine after consuming Iron (Iron Acetyltransferrin)?

Depending on the reaction of the Iron (Iron Acetyltransferrin) after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Iron (Iron Acetyltransferrin) not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

Is Iron (Iron Acetyltransferrin) addictive or habit forming?

Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.

advertisement

Review

sdrugs.com conducted a study on Iron (Iron Acetyltransferrin), and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Iron (Iron Acetyltransferrin) consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.

Visitor reports

Visitor reported useful

No survey data has been collected yet

Visitor reported side effects

No survey data has been collected yet

Visitor reported price estimates

No survey data has been collected yet

Visitor reported frequency of use

No survey data has been collected yet

One visitor reported doses

What is the dose of Iron (Iron Acetyltransferrin) drug you are taking?
According to the survey conducted among sdrugs.com website users, the maximum number of people are using the following dose 1-5mg. Few medications come in only one or two doses. Few are specific for adult dose and child dose. The dose of the medicine given to the patient depends on the severity of the symptom/disease. There can be dose adjustments made by the doctor, based on the progression of the disease. Follow-up is important.
Visitors%
1-5mg1
100.0%

Visitor reported time for results

No survey data has been collected yet

Visitor reported administration

No survey data has been collected yet

Visitor reported age

No survey data has been collected yet

Visitor reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 19 here

The information was verified by Dr. Arunabha Ray, MD Pharmacology

© 2002 - 2020 "sdrugs.com". All Rights Reserved